eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 103 blog entries.
17 04, 2018

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018

2018-04-17T15:40:32+00:00

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018 PALO ALTO, Calif., April 17, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis [...]

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018 2018-04-17T15:40:32+00:00
2 04, 2018

Eiger BioPharmaceuticals to Participate in Conferences in April

2018-04-02T12:18:56+00:00

Eiger BioPharmaceuticals to Participate in Conferences in April PALO ALTO, Calif. – April 2, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming investor, scientific, and orphan drug conferences in April. C. Wainwright Global Life Science Conference at [...]

Eiger BioPharmaceuticals to Participate in Conferences in April 2018-04-02T12:18:56+00:00
26 03, 2018

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia

2018-03-26T12:15:20+00:00

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia PALO ALTO, Calif., March 26, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2, multi-center study of [...]

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia 2018-03-26T12:15:20+00:00
21 03, 2018

Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program

2018-03-21T13:45:01+00:00

Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program - Phase 3 D-LIVR Trial Planned to Initiate in Second Half 2018 PALO ALTO, Calif., March 21, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today positive FDA guidance from [...]

Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program 2018-03-21T13:45:01+00:00
12 03, 2018

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

2018-03-12T13:42:15+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Hepatitis Delta Virus Program Moving into Phase 3 in 2018 Phase 2 Clinical Results Planned from Three Pipeline Programs in 2018 Cash Runway Extends Through Mid-2019 PALO ALTO, Calif., March 12, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 2018-03-12T13:42:15+00:00
6 03, 2018

Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March

2018-03-06T15:15:03+00:00

Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March PALO ALTO, Calif. – March 6, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business [...]

Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March 2018-03-06T15:15:03+00:00
5 03, 2018

Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting

2018-03-05T16:00:23+00:00

Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting PALO ALTO, Calif., March 5, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at The International Liver Congress™ [...]

Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting 2018-03-05T16:00:23+00:00
6 02, 2018

Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February

2018-02-06T21:17:32+00:00

Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February PALO ALTO, Calif. – February 6, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two [...]

Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February 2018-02-06T21:17:32+00:00
16 01, 2018

Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint

2018-01-16T13:17:12+00:00

Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint - End of Phase 2 Meeting Scheduled for HDV in February 2018 - Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif., January 16, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development [...]

Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint 2018-01-16T13:17:12+00:00
8 01, 2018

Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors

2018-01-08T14:36:31+00:00

Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors PALO ALTO, Calif., January 8, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors.  Mr. Mayer is a pharmaceutical [...]

Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors 2018-01-08T14:36:31+00:00

About Us

EigerBio Logo

We are a values-driven company that works to embody Integrity, Passion, Accountability, Creativity, and Teamwork in the pursuit of our mission.

Privacy Policy | Terms & Conditions

Therapeutic Areas

Hepatitis Delta
Post-bariatric Hypoglycemia
Lymphedema
Home
About Eiger
Pipeline
News
Investors
Careers
Contact Us

Contact

Eiger BioPharmaceuticals, Inc.
350 Cambridge Ave, Suite 350
Palo Alto, CA  94306

Phone: 1-877-899-2051
Fax: 650-618-1621
Email: info@eigerbio.com

Click Here for Directions

Eiger BioPharmaceuticals © 2018 | All Rights Reserved
Toggle Sliding Bar Area